Agentic AI: The Race to a Touchless Revenue Cycle

McKinsey's analysis of agentic AI in the healthcare revenue cycle projects that AI-driven automation could reduce cost-to-collect by 30 to 60 percent — a range that, if realized, would fundamentally restructure how physician practices manage their revenue operations. The report envisions a "touchless" revenue cycle where AI agents handle eligibility verification, claim submission, denial detection, and initial appeal generation with minimal human intervention. For practices spending an ever-growing share of their resources on administrative overhead, the McKinsey analysis offers both a compelling vision and a set of questions that deserve careful consideration.

What McKinsey Sees

The McKinsey analysis distinguishes between conventional automation — rules-based systems that handle predictable, repetitive tasks — and agentic AI, which can navigate ambiguity, make contextual decisions, and adapt to novel situations. In the revenue cycle context, agentic AI would go beyond auto-populating claim forms to activities like:

• Analyzing clinical documentation to predict which claims are likely to be denied before submission
• Identifying the specific documentation gaps or coding issues that trigger denials with specific payers
• Generating initial appeal narratives that reference relevant clinical guidelines and payer-specific criteria
• Prioritizing denied claims based on likelihood of overturn and dollar value
• Learning from appeal outcomes to improve future predictions and recommendations

The 30 to 60 percent cost reduction range reflects the potential for AI to handle the high-volume, lower-complexity work that currently consumes the majority of revenue cycle staff time, freeing human expertise for the complex cases, payer negotiations, and strategic decisions that require clinical judgment and interpersonal skill.

The Denial Management Implications

For physician practices, the most immediately relevant aspect of McKinsey's analysis is its implications for denial management. Current denial management is labor-intensive, inconsistent, and often reactive — practices discover denials through EOBs, manually evaluate whether to appeal, and craft appeal letters that may or may not reference the most relevant clinical evidence. AI-assisted denial management could shift this paradigm in several ways.

Predictive denial detection means identifying at-risk claims before they are denied — when intervention is cheapest and most effective. Automated appeal generation does not mean replacing clinical judgment in the appeal but rather ensuring that every appeal consistently includes the relevant clinical guidelines, payer policy citations, and patient-specific evidence that strengthen the case. Outcome-based learning means that each appeal outcome improves the system's recommendations for future similar cases.

Appropriate Expectations

The McKinsey projection deserves healthy skepticism alongside interest. Healthcare revenue cycle processes are deeply entangled with payer-specific rules, local coverage determinations, state regulations, and clinical complexity that varies by specialty. AI systems that perform well on standardized, high-volume transactions may struggle with the edge cases and clinical nuances that characterize many denial scenarios.

The 30 to 60 percent cost reduction range is also a projection, not a documented outcome. Real-world implementation will depend on data quality, integration with existing EHR and practice management systems, staff adoption, and the ongoing evolution of payer behavior in response to AI-driven submissions. Practices should evaluate AI-assisted revenue cycle tools based on demonstrated outcomes in comparable practice settings, not on projections alone.

What This Means for Practices Today

Regardless of when the full "touchless revenue cycle" arrives, the direction McKinsey describes creates a clear imperative for practices: the data infrastructure you build today determines your ability to leverage AI-assisted tools tomorrow. Practices with systematic denial tracking, structured clinical documentation, and organized appeal workflows will be positioned to adopt AI-assisted denial management as the technology matures. Those without this foundation will face the same barriers to AI adoption that they currently face with basic process improvement — not a technology gap, but a data and workflow gap.